Aduro BioTech (ADRO) Trading Up 5.8%

Aduro BioTech Inc (NASDAQ:ADRO)’s share price was up 5.8% on Friday . The stock traded as high as $7.30 and last traded at $7.30. Approximately 637,524 shares traded hands during mid-day trading, an increase of 52% from the average daily volume of 418,731 shares. The stock had previously closed at $6.90.

Several equities analysts have recently weighed in on ADRO shares. HC Wainwright set a $18.00 price objective on Aduro BioTech and gave the company a “buy” rating in a report on Wednesday, November 1st. Oppenheimer started coverage on Aduro BioTech in a report on Monday, October 30th. They issued a “buy” rating and a $15.00 price objective for the company. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, William Blair restated an “outperform” rating on shares of Aduro BioTech in a report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $17.71.

The company has a market cap of $525.66, a P/E ratio of -5.37 and a beta of 3.52.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.03). Aduro BioTech had a negative net margin of 548.92% and a negative return on equity of 39.28%. The firm had revenue of $3.79 million during the quarter, compared to analyst estimates of $4.04 million. During the same quarter last year, the business posted ($0.54) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis. equities analysts predict that Aduro BioTech Inc will post -1.28 EPS for the current year.

In related news, COO Gregory W. Schafer sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $7.97, for a total value of $159,400.00. Following the completion of the sale, the chief operating officer now directly owns 155,677 shares in the company, valued at approximately $1,240,745.69. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stephen T. Isaacs sold 20,200 shares of the firm’s stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $7.98, for a total transaction of $161,196.00. Following the completion of the sale, the insider now owns 190,321 shares of the company’s stock, valued at $1,518,761.58. The disclosure for this sale can be found here. Insiders sold a total of 267,714 shares of company stock valued at $2,251,452 over the last quarter. 6.60% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of the business. Legal & General Group Plc lifted its position in Aduro BioTech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 1,043 shares during the last quarter. Voya Investment Management LLC lifted its position in Aduro BioTech by 15.3% during the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after acquiring an additional 2,515 shares during the last quarter. Nationwide Fund Advisors lifted its position in Aduro BioTech by 12.5% during the second quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 2,567 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Aduro BioTech by 12.5% during the second quarter. The Manufacturers Life Insurance Company now owns 33,964 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 3,769 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its position in Aduro BioTech by 12.7% during the second quarter. Alliancebernstein L.P. now owns 46,300 shares of the biotechnology company’s stock worth $528,000 after acquiring an additional 5,200 shares during the last quarter. Hedge funds and other institutional investors own 45.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3146472/aduro-biotech-adro-trading-up-5-8.html.

About Aduro BioTech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.